Cargando…

Topical Melatonin for Treatment of Androgenetic Alopecia

BACKGROUND: In the search for alternative agents to oral finasteride and topical minoxidil for the treatment of androgenetic alopecia (AGA), melatonin, a potent antioxidant and growth modulator, was identified as a promising candidate based on in vitro and in vivo studies. MATERIALS AND METHODS: One...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Tobias W, Trüeb, Ralph M, Hänggi, Gabriella, Innocenti, Marcello, Elsner, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681103/
https://www.ncbi.nlm.nih.gov/pubmed/23766606
http://dx.doi.org/10.4103/0974-7753.111199
_version_ 1782273202104303616
author Fischer, Tobias W
Trüeb, Ralph M
Hänggi, Gabriella
Innocenti, Marcello
Elsner, Peter
author_facet Fischer, Tobias W
Trüeb, Ralph M
Hänggi, Gabriella
Innocenti, Marcello
Elsner, Peter
author_sort Fischer, Tobias W
collection PubMed
description BACKGROUND: In the search for alternative agents to oral finasteride and topical minoxidil for the treatment of androgenetic alopecia (AGA), melatonin, a potent antioxidant and growth modulator, was identified as a promising candidate based on in vitro and in vivo studies. MATERIALS AND METHODS: One pharmacodynamic study on topical application of melatonin and four clinical pre-post studies were performed in patients with androgenetic alopecia or general hair loss and evaluated by standardised questionnaires, TrichoScan, 60-second hair count test and hair pull test. RESULTS: Five clinical studies showed positive effects of a topical melatonin solution in the treatment of AGA in men and women while showing good tolerability: (1) Pharmacodynamics under once-daily topical application in the evening showed no significant influence on endogenous serum melatonin levels. (2) An observational study involving 30 men and women showed a significant reduction in the degree of severity of alopecia after 30 and 90 days (P < 0.001) based on questionnaires completed by investigators and patients. (3) Using a digital software-supported epiluminescence technique (TrichoScan) in 35 men with AGA, after 3 and 6 months in 54.8% to 58.1% of the patients a significant increase of hair density of 29% and 41%, respectively was measured (M0: 123/cm(2); M3: 159/cm(2); M6: 173/cm(2);) (P < 0,001). (4) In 60 men and women with hair loss, a significant reduction in hair loss was observed in women, while hair loss in men remained constant (P < 0.001). (5) In a large, 3-month, multi-center study with more than 1800 volunteers at 200 centers, the percentage of patients with a 2- to 3-fold positive hair-pull test decreased from 61.6% to 7.8%, while the percentage of patients with a negative hair-pull test increased from 12.2.% to 61.5% (P < 0.001). In addition, a decrease in seborrhea and seborrheic dermatitis of the scalp was observed. CONCLUSIONS: Since safety and tolerability in all of the studies was good, the topical application of a cosmetic melatonin solution can be considered as a treatment option in androgenetic alopecia.
format Online
Article
Text
id pubmed-3681103
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36811032013-06-13 Topical Melatonin for Treatment of Androgenetic Alopecia Fischer, Tobias W Trüeb, Ralph M Hänggi, Gabriella Innocenti, Marcello Elsner, Peter Int J Trichology Original Article BACKGROUND: In the search for alternative agents to oral finasteride and topical minoxidil for the treatment of androgenetic alopecia (AGA), melatonin, a potent antioxidant and growth modulator, was identified as a promising candidate based on in vitro and in vivo studies. MATERIALS AND METHODS: One pharmacodynamic study on topical application of melatonin and four clinical pre-post studies were performed in patients with androgenetic alopecia or general hair loss and evaluated by standardised questionnaires, TrichoScan, 60-second hair count test and hair pull test. RESULTS: Five clinical studies showed positive effects of a topical melatonin solution in the treatment of AGA in men and women while showing good tolerability: (1) Pharmacodynamics under once-daily topical application in the evening showed no significant influence on endogenous serum melatonin levels. (2) An observational study involving 30 men and women showed a significant reduction in the degree of severity of alopecia after 30 and 90 days (P < 0.001) based on questionnaires completed by investigators and patients. (3) Using a digital software-supported epiluminescence technique (TrichoScan) in 35 men with AGA, after 3 and 6 months in 54.8% to 58.1% of the patients a significant increase of hair density of 29% and 41%, respectively was measured (M0: 123/cm(2); M3: 159/cm(2); M6: 173/cm(2);) (P < 0,001). (4) In 60 men and women with hair loss, a significant reduction in hair loss was observed in women, while hair loss in men remained constant (P < 0.001). (5) In a large, 3-month, multi-center study with more than 1800 volunteers at 200 centers, the percentage of patients with a 2- to 3-fold positive hair-pull test decreased from 61.6% to 7.8%, while the percentage of patients with a negative hair-pull test increased from 12.2.% to 61.5% (P < 0.001). In addition, a decrease in seborrhea and seborrheic dermatitis of the scalp was observed. CONCLUSIONS: Since safety and tolerability in all of the studies was good, the topical application of a cosmetic melatonin solution can be considered as a treatment option in androgenetic alopecia. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3681103/ /pubmed/23766606 http://dx.doi.org/10.4103/0974-7753.111199 Text en Copyright: © International Journal of Trichology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Fischer, Tobias W
Trüeb, Ralph M
Hänggi, Gabriella
Innocenti, Marcello
Elsner, Peter
Topical Melatonin for Treatment of Androgenetic Alopecia
title Topical Melatonin for Treatment of Androgenetic Alopecia
title_full Topical Melatonin for Treatment of Androgenetic Alopecia
title_fullStr Topical Melatonin for Treatment of Androgenetic Alopecia
title_full_unstemmed Topical Melatonin for Treatment of Androgenetic Alopecia
title_short Topical Melatonin for Treatment of Androgenetic Alopecia
title_sort topical melatonin for treatment of androgenetic alopecia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681103/
https://www.ncbi.nlm.nih.gov/pubmed/23766606
http://dx.doi.org/10.4103/0974-7753.111199
work_keys_str_mv AT fischertobiasw topicalmelatoninfortreatmentofandrogeneticalopecia
AT truebralphm topicalmelatoninfortreatmentofandrogeneticalopecia
AT hanggigabriella topicalmelatoninfortreatmentofandrogeneticalopecia
AT innocentimarcello topicalmelatoninfortreatmentofandrogeneticalopecia
AT elsnerpeter topicalmelatoninfortreatmentofandrogeneticalopecia